Sign inJoin waitlistJoin the waitlist

Edward Briercheck

Physician · BINNEY MEDICAL ASSOCIATES

Credentials: · · ·

History

Dana-Farber Cancer Institute
2025–Present

Dana-Farber Cancer Institute
2023–2024
Hematology & Oncology
University of Washington
2020–2023
Harvard School of Public Health
2018–2020
Internal Medicine
Boston University Medical Center
2015–2018
Ohio State Univ Coll of Med
2011–2015
University of Toledo
2003–2007
Resident
Boston University Medical Center

Research

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Cancer immunology · 2013 · 253 citations
Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue
Immunity · 2010 · 172 citations
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22
Blood · 2009 · 103 citations

MC
Michael Caligiuri
11 papers
Aharon Freud
7 papers · 4 as a resident
Susan McClory
5 papers · 2 as a resident
Yasodha Natkunam
4 papers
DW
David Weinstock
3 papers
GN
Gerard Nuovo
3 papers
Oscar Silva
3 papers · 1 as a fellow
SS
Steven Scoville
3 papers
Ansel Nalin
2 papers
Don Benson
2 papers
Edus Warren
2 papers
JC
Jordan Cole
2 papers

Grants

Scaling Lymphoma Diagnosis: A Cost-Effective Gene Expression Assay for Broad Implementation
National Cancer Institute · R44
Contact PI · $2.3M · Raiz Diagnostics, Inc.
2025–2027